Are There Clinically Significant Differences Among the Third Generation EGFR Inhibitors?
Article
Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.
Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?
Article
Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).
Should Third Generation EGFR Inhibitors Be Used Before First Generation EGFR TKIs or After Progression?
Article
Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.
Should EGFR TKI Therapy be Continued Beyond Progression?
Article
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
The Potential Value of Repeat Biopsies in Acquired Resistance
Article
MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.
Patterns of Acquired Resistance to EGFR TKIs in EGFR Mutation-Positive NSCLC
Article
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
My Top Five Highlights in Lung Cancer from 2014
Article
An annual tradition is a reflection on the key developments in the field over the past year. This year saw some major advances, with several of the biggest changes bubbling just below the surface and about to really break out in 2015. So without further adieu, here's my list.
For those who wish to access the pdf, it's here: Top 5 Highlights in Lung Cancer 2014
Agree? Disagree? What's highest on your wish list for 2015?
Novel EGFR Inhibitors in the Setting of Acquired Resistance
Article
Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.
[powerpress]
Treating EGFR Patients After Tarceva Stops Working
Article
Tarceva (erlotinib) has greatly helped EGFR positive lung cancer patients, but eventually it stops working. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center talks about the next generation EGFR inhibitors that may soon become available. February 2014.
[powerpress]